However, within the context of PD‐1/PD‐L1 blockade resistance, this regulatory response could potentially have adverse effects by fostering a more immunosuppressive tumor microenvironment and further compromising T cell functionality and immune surveillance. The gene discussed is RPL17; the disease is neoplasm.